Objective: Hepatic steatosis is common in HIV-infected individuals. Magnetic resonance spectroscopy (MRS) is the preferred noninvasive method for hepatic steatosis measurement but is expensive. Controlled attenuation parameter (CAP) also assesses hepatic steatosis and is conveniently performed concomitantly with transient elastography. We aimed to assess the accuracy of CAP in the setting of HIV infection.
Introduction
Hepatic steatosis is common in HIV-infected individuals, and its prevalence is expected to increase with the rise of obesity and metabolic syndrome and the aging of the HIVinfected population [1] [2] [3] . Although liver biopsy is the gold standard for detecting and staging hepatic steatosis, it is infrequently performed in HIV-infected patients without viral hepatitis coinfection. Magnetic resonance spectroscopy (MRS) is the preferred noninvasive modality to detect and quantify hepatic steatosis but is costly and not readily available in resource-limited settings [4] .
Fibroscan (Echosens, Paris, France)-measured transient elastography is increasingly utilized to estimate liver fibrosis. Controlled attenuation parameter (CAP) quantifies hepatic steatosis by measuring the attenuation of ultrasound waves traveling through the liver at the radio frequency of the Fibroscan probe. Because it is conveniently performed simultaneously with Fibroscan-transient elastography and is relatively inexpensive, CAP is an attractive method to measure hepatic steatosis. Indeed, CAP has been evaluated as a surrogate for histologic hepatic steatosis among patients with a variety of liver diseases [5] [6] [7] and is increasingly being used to screen for hepatic steatosis in HIV-infected persons [8] [9] [10] [11] [12] . However, there are no published data on the accuracy of CAP in the setting of HIV infection. Therefore, the objectives of this study were to examine the correlation of CAP and MRS-measured hepatic steatosis (MRS-HS) in a cohort of patients with and without HIV infection and to determine whether HIV altered this correlation.
Patients and methods
Participants were recruited from the Northern California site of the Women's Interagency HIV Study (WIHS) and the study of visceral adiposity, HIV, and hepatitis C virus (HCV) (VAHH): biologic mediators of hepatic steatosis. Both WIHS and VAHH enrolled participants with HIV monoinfection, HCV monoinfection, HIV/HCV coinfection, and those with neither infection. Recruitment and study design details of both studies have previously been described [13, 14] .
From October 2013 through July 2015, 85 study participants enrolled in the WIHS MRS steatosis substudy and VAHH who had both MRS and CAP measurements available within a median of 14 days (range : 0-294) were included in analysis. MRI was performed on a 3Twhole body scanner (General Electric Healthcare, Waukesha, Wisconsin USA), and MRS was acquired from an 8 ml voxel similarly to prior reports, with a 64-acquisition time series of spectra [15] . Spectra were automatically phase, frequency, motion, and T2 relaxation time corrected [16] [17] [18] . Quality was visually confirmed by a magnetic resonance spectroscopist with over 20-years' experience. We calculated liver fat fraction from the corrected MRS measures of CH 2 and CH 3 lipids and of water as the total lipids/(total lipids þ water). Visceral adipose tissue (VAT) and abdominal subcutaneous adipose tissue (SAT) volumes were generated based on magnetic resonance slices located at the discs between lumbar vertebrae L2-3, L3-4, and L4-5. Of 85 study participants who underwent CAP assessment (Fibroscan), 82 had valid measurements (39 HIV monoinfected, seven HCV monoinfected, 21 HIV/HCV coinfected, and 15 uninfected) and were included in the analysis.
Race, ethnicity, alcohol consumption, smoking history, marijuana use, and history of injection drug use were obtained through self-report. Alcohol use was categorized as: none; light-moderate (0-12 drinks/week); or heavy (>12 drinks/week). The homeostatic model assessment of insulin resistance was calculated using 8-h fasting insulin and glucose values. The aspartate aminotransferase-to-platelet ratio index and the FIB-4 index were used to estimate liver fibrosis [19, 20] . Probable cirrhosis was defined as aminotransferase-toplatelet ratio index more than 2 or FIB-4 more than 3.25. HIV infection was defined by documentation of a positive HIV enzyme immunoassay confirmed with western blot, and chronic HCV infection was defined as serum HCV antibody and HCV RNA positive.
Both MRS-HS and CAP-measured hepatic steatosis (CAP-HS) had right-skewed distributions, and therefore the results were log transformed. To compare MRS-HS and CAP-HS, we standardized log-transformed values to a mean of 0 and SD of 1. We used concordance correlation coefficients to compare the standardized measurements and linear regression to examine the factors associated with CAP-HS and MRS-HS. The regression coefficients and 95% confidence intervals (CI) are reported as changes in SD units of the log-transformed MRS or CAP values.
Next, we used receiver operating characteristics (ROC) analysis to evaluate the ability of the CAP cut-off of at least 238 dB/m to detect at least mild hepatic steatosis, defined as MRS liver fat fraction of at least 0.05. This CAP cut-off was selected because it has been validated in HIV-uninfected patients and has been used in studies of hepatic steatosis in HIV-infected individuals [5, 8, 10, 12] . Kappa coefficient was used to measure agreement between hepatic steatosis diagnosed by CAP or MRS. We used the x 2 and the Wilcoxon rank-sum tests to compare the characteristics of participants with concordant and discordant MRS and CAP values. Specifically, participants were stratified by MRS into no hepatic steatosis and hepatic steatosis groups; within these groups, participants with low CAP (no hepatic steatosis) and high CAP (hepatic steatosis) were compared. Finally, factors associated with false-positive CAP-HS were evaluated using logistic regression. Statistical analyses were performed using SAS system, version 9.4 (Cary, North Carolina, USA) and STATA version 12.1 (College Station, Texas, USA). Table 1 shows characteristics of the study population and factors associated with CAP-HS and MRS-HS. The median age was 56 years, 71% were women; over half were African American; 50% were overweight or obese (median: BMI 25 kg/m 2 ), and only 10% reported heavy alcohol use. The majority (98%) were on highly active antiretroviral therapy. The CAP mean was 232 dB/m and standard deviation (SD) 51 dB/m, and the MRS mean liver fat fraction was 0.04 with SD 0.05. On univariate analysis, nonwhite, non-African American race was associated with significantly higher CAP-HS and MRS-HS, as were increasing BMI, waist circumference, VAT, SAT, and homeostatic model assessment of insulin Controlled attenuation parameter Price et al. 2121 Table 1 . Demographic and clinical characteristics of study population and factors associated with controlled attenuation parameter-measured hepatic steatosis and magnetic resonance spectroscopy-measured hepatic steatosis (HS). resistance (Table 1) . These factors remained significantly associated with CAP-HS and MRS-HS after adjusting for age and sex. History of clinical AIDS was associated with significantly higher MRS-HS but not CAP-HS, although this was only borderline significant after adjusting for age and sex (P ¼ 0.05).
Results

Correlation of controlled attenuation parameter and magnetic resonance spectroscopy by HIV and HCV status
In the entire group, CAP-HS increased with increasing MRS-HS, and we found moderate agreement between the two continuous measurements, with a concordance correlation coefficient (r c ) ¼ 0.63 (P < 0.001). When stratified by disease status, agreement between CAP-HS and MRS-HS was highest among the HIV-monoinfected (r c ¼ 0.67; P < 0.001) and HIV/HCV-coinfected groups (r c ¼ 0.67; P < 0.001; Fig. 1a) . CAP detected at least mild hepatic steatosis, defined as MRS liver fat fraction at least 0.05, with an area under the ROC curve of 0.85 (95% CI: 0.76-0.95) in the entire cohort and 0.88 (95% CI: 0.78-0.99) in the HIV-monoinfected group. Using a CAP cutoff of at least 238 dB/m, sensitivity and specificity for at least mild hepatic steatosis were 84% (95% CI: 60-97%) and 75% (95% CI: 62-85%), respectively, in the entire cohort and 89% (95% CI: 52-100%) and 80% (95% CI: 61-92%), respectively, in the HIV-monoinfected group.
Controlled attenuation parameterand magnetic resonance spectroscopy discordance The prevalence of hepatic steatosis in our cohort differed depending on the modality used to assess hepatic steatosis: 23% had hepatic steatosis using MRS and 39% had hepatic steatosis using CAP. Among the 63 individuals without hepatic steatosis on MRS, 16 (25%) were categorized as having hepatic steatosis on CAP, whereas among the 19 with hepatic steatosis using MRS, three (16%) were identified as not having hepatic steatosis using CAP, yielding a Kappa coefficient of 0.47 (Fig. 1b) 
Discussion
The major finding of our study was that CAP-HS and MRS-HS correlated moderately well and that HIV serostatus did not adversely alter the correlation. Furthermore, similar clinical factors were associated with both MRS-HS and CAP-HS, primarily body composition, and metabolic factors known to be associated with hepatic steatosis. Although our cohort is small, the findings suggest that CAP is an acceptable noninvasive surrogate for hepatic steatosis in large studies of HIVinfected individuals. However, CAP overestimated hepatic steatosis prevalence, and higher BMI and VAT were associated with increased odds of false-positive CAP.
Nonalcoholic fatty liver disease refers to hepatic steatosis in the absence of excessive alcohol use. It is the most common cause of liver disease in Western industrialized countries, and prevalence is increasing in parallel to the obesity epidemic [21] . Given the scope of the disease, affecting an estimated 30% of the US population [22] , a well tolerated, inexpensive, reliable method of hepatic steatosis screening is critical. This is especially important in the setting of HIV infection: several studies indicate hepatic steatosis is common in HIV-infected individuals, ranging from 28% to 54% in HIV-monoinfected groups [8, 12, 14, [23] [24] [25] , but the pathophysiology and implications of hepatic steatosis in this population are not well understood.
Although CAP is used to screen for hepatic steatosis in HIV-infected populations, it has not been validated for this purpose. Multiple studies have compared CAP-HS with histologic hepatic steatosis in patients with a variety of underlying liver diseases. In a meta-analysis including 2735 patients from 19 studies, CAP demonstrated good performance in detecting hepatic steatosis (defined as !5% of hepatocytes affected on histology) with an area under the ROC of 0.82 [26] . However, HIV-infected patients were not included. Moreover, the authors found that patients with nonalcoholic fatty liver disease had higher CAP values than patients with other causes of liver disease such as hepatitis C or B virus, independent of histologic hepatic steatosis. Therefore, validation of CAP within a cohort of patients with HIV infection is important.
Our results showing that CAP-HS correlated moderately well with MRS-HS are similar to other studies comparing CAP-HS and MRS-HS in HIV-uninfected populations, in which the correlation coefficients ranged from 0.50 to 0.69 [27] [28] [29] . There was no significant correlation between CAP and MRS in the HCVmonoinfected group, likely because of the very small sample size in this subgroup. Our finding that CAP was able to detect at least mild hepatic steatosis with an area under the ROC of 0.85 in the whole cohort and 0.88 in the HIV-monoinfected group is also consistent with published literature, with area under the ROC for detection of at least mild hepatic steatosis ranging from 0.80 to 0.88 using histology as the reference standard [27, [30] [31] [32] and 0.83-0.90 using MRS as the reference standard [33] .
Notably, we found that CAP was more likely to overestimate the presence of hepatic steatosis as BMI increased. Others have similarly reported this; the recent meta-analysis found increasing BMI to be associated with significantly higher odds of a discrepancy between CAP and histologic hepatic steatosis [26] . This highlights a key limitation of CAP and the importance of exercising caution when comparing hepatic steatosis prevalence across studies and patient populations, especially when varying modalities are used to assess hepatic steatosis. A limitation to our study was the lack of a liver biopsy to correlate CAP results with histology. However, we used MRI as our reference standard, which is considered the most reliable noninvasive modality for detecting hepatic steatosis [4] , and similar factors were associated with both CAP-HS and MRS-HS. Another limitation is that the CAP and MRS measures may not have been taken from the same location in the liver -heterogeneity of steatosis may have led to some of the discordance observed [15] .
In summary, we found that CAP-hepatic steatosis and MRS-hepatic steatosis correlated moderately well in our cohort of patients with and without HIV and HCV infection. Importantly, HIV infection did not adversely impact CAP performance in detecting hepatic steatosis, but participants with higher BMI were more likely to be falsely identified as having hepatic steatosis using CAP. Our results support the use of CAP for initial hepatic steatosis screening in large cohorts of HIV-infected individuals. However, optimal CAP cut-offs are needed, especially if CAP results are used to make individual patient decisions. Further evaluations of factors that could improve CAP accuracy and interpretation of longitudinal changes in CAP are warranted.
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